Product Information
LIALDA DR 1.2 GM TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $8.9465 per EA under NDC 54092047612. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jan 16, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the mesalamine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1.2 g/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
54092047612
Classification
Brand
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
New Drug (NDA)
FDA Application
NDA022000FDA Approved
1/16/2007
TE Code
AB
On Market Since
1/16/2007
Pharmacological Classes
Price Statistics
The NADAC for LIALDA DR 1.2 GM TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 45.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.9465 per EA |
|---|---|
| All-time high | $9.0779 (Dec 14, 2022) |
| All-time low | $6.1316 (Nov 28, 2013) |
| 52-week high | $8.9766 |
| 52-week low | $8.9463 |
| Median price | $8.9747 |
| Average price | $8.4968 |
| Largest weekly change | +9.0% (Jun 14, 2017) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 91% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LIALDA DR 1.2 GM TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LIALDA DR 1.2 GM TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $8.9465 per EA (NDC 54092047612), effective Sep 30, 2026.
How has the price of LIALDA DR 1.2 GM TABLET changed over time?
Over the history we have for it, the NADAC for LIALDA DR 1.2 GM TABLET has risen 45.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LIALDA DR 1.2 GM TABLET?
Since Nov 28, 2013, the NADAC for LIALDA DR 1.2 GM TABLET has ranged from a low of $6.1316 (Nov 28, 2013) to a high of $9.0779 (Dec 14, 2022), with a median of $8.9747 per EA.
Are there cheaper alternatives to LIALDA DR 1.2 GM TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MESALAMINE DR 1.2 GM TABLET, is $0.7809 per EA — about 91% below LIALDA DR 1.2 GM TABLET.
Who manufactures LIALDA DR 1.2 GM TABLET?
LIALDA DR 1.2 GM TABLET (NDC 54092047612) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.